MWNA
AKCA

Marshall Wace North America’s Akcea Therapeutics Inc AKCA Stock Holding History

Marshall Wace North America’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,736
Closed -$106K – 1827
2019
Q1 		$106K Buy
+3,736
New +$109K ﹤0.01% 1106

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Marshall Wace North America's AKCA Position: Q2 2019 in Review

Marshall Wace North America sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 3,736 shares — an estimated $106K sold.

Marshall Wace North America first reported a position in AKCA in Q1 2019 and held it in 1 quarter. The position peaked at $106K in Q1 2019. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

  • Marshall Wace North America reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 3,736 Akcea Therapeutics Inc shares in Q2 2019, an estimated $106K.
  • Marshall Wace North America first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 1 quarter.
  • Marshall Wace North America's Akcea Therapeutics Inc position peaked at $106K in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.